Posttranslational modifications of histones such as methylation, acetylation and phosphorylation regulate chromatin structure and gene expression. Here we show that protein-kinase-C-related kinase 1 (PRK1) phosphorylates histone H3 at threonine 11 (H3T11) upon ligand-dependent recruitment to androgen receptor target genes. PRK1 is pivotal to androgen receptor function because PRK1 knockdown or inhibition impedes androgen receptor-dependent transcription. Blocking PRK1 function abrogates androgeninduced H3T11 phosphorylation and inhibits androgen-induced demethylation of histone H3. Moreover, serine-5-phosphorylated RNA polymerase II is no longer observed at androgen receptor target promoters. Phosphorylation of H3T11 by PRK1 accelerates demethylation by the Jumonji C (JmjC)-domain-containing protein JMJD2C. Thus, phosphorylation of H3T11 by PRK1 establishes a novel chromatin mark for gene activation, identifying PRK1 as a gatekeeper of androgen receptor-dependent transcription. Importantly, levels of PRK1 and phosphorylated H3T11 correlate with Gleason scores of prostate carcinomas. Finally, inhibition of PRK1 blocks proliferation of androgen receptor-induced tumour cell proliferation, making PRK1 a promising therapeutic target.
The amino (N)-terminal tails of histones are subject to a plethora of posttranslational modifications such as methylation, acetylation and phosphorylation by specific chromatin-modifying enzymes 1 . During gene expression, these modifications influence chromatin structure to facilitate the assembly of the RNA polymerase II transcription machinery 1,2 . Androgen receptor-dependent gene expression is characterized by changes in chromatin modifications such as removal of repressive methyl marks from lysine 9 of histone H3 (H3K9) 3, 4 . The demethylases JMJD2C (ref. 4 ) and lysine-specific demethylase 1 (LSD1) (ref. 3) cooperate to remove trimethyl and di-and monomethyl marks from H3K9, respectively. In addition, other chromatin modifications, such as acetylation of lysines 9 and 14 of histone H3 (H3K9/K14) (ref. 5) , are necessary for androgen receptor-dependent transcription. However, little is known about the upstream regulators that govern these histone modifications. Because PRK1 controls androgen receptor-dependent gene expression 6 , we asked whether PRK1 signalling regulates histone modifications at androgen receptor target genes.
RESULTS

PRK1 controls androgen receptor-dependent gene expression
To initiate our study, we analysed the effect of PRK1 knockdown on the expression of endogenous androgen receptor target genes. LNCaP prostate tumour cells were transduced with lentiviruses expressing microRNAs (miRNAs) directed against PRK1, which results in an (miRNAs) directed against PRK1, which results in an efficient and specific downregulation of endogenous PRK1 (Fig. 1a , right panel). Quantitative polymerase chain reaction with reverse transcription (QRT-PCR) demonstrates that the reduction of PRK1 levels strongly impairs androgen-induced expression of endogenous androgen receptor target genes such as prostate-specific antigen (PSA) or kallikrein 2 (KLK2), but does not affect unrelated control genes (Fig. 1a , left panel, and Supplementary Information, Fig. S1a ). In addition, treatment with the PRK1 inhibitor Ro318220 (ref. 6 ) severely impedes androgen-induced expression of androgen receptor target genes, showing that the kinase activity of PRK1 is essential for androgen receptor function (Fig. 1b, and Supplementary Information, Fig. S1b) . Similarly, miRNA-mediated knockdown of PRK1 or treatment with Ro318220 results in a strong decrease in ligand-induced expression of various androgen receptor-dependent reporters ( Supplementary  Information, Fig. S1c, d ).
PRK1 associates with chromatin
To investigate whether PRK1 associates with chromatin in vivo, LNCaP cells were subjected to chromatin immunoprecipitation (ChIP) in the presence or absence of the androgen receptor agonist R1881. PRK1 and androgen receptor associate with the androgen response elements (AREs) located in the promoters of the PSA and KLK2 genes in a ligand-dependent manner (Fig. 1c, left panel) . Recruitment of PRK1 to chromatin is specific, because DNA corresponding neither to the promoters of the unrelated GAPDH and U6 genes (Fig. 1c, left panel) nor to a region between the enhancer and promoter or exon 4 of the PSA gene is enriched ( Supplementary Information, Fig. S1e ). To show that PRK1 and androgen receptor are present in the same complex on the PSA and KLK2 promoters, R1881-treated LNCaP cells were subjected to sequential ChIP (Re-ChIP), first with α-androgen receptor and then with α-PRK1 antibody. Importantly, the ARE-containing regions are specifically enriched, demonstrating that PRK1 and androgen receptor form a complex on chromatin in a ligand-dependent manner (Fig. 1c , right panel, and Supplementary Information, Fig. S1f ).
PRK1 phosphorylates H3T11
To understand how association of PRK1 and androgen receptor with chromatin results in increased gene expression, we tested whether PRK1 directly phosphorylates the N-terminal tail of histone H3. Myc-PRK1 and the flag-tagged kinase dead mutant PRK1 K644E (ref. 6) were immunoprecipitated from 293 cell lysates with α-myc or α-flag antibody, respectively ( Supplementary Information, Fig. S1g, h ) and incubated with bacterially expressed and purified glutathione-S-transferase (GST)-H3. 1-44 or GST control protein. GST-H3 1-44 is phosphorylated by PRK1 but not by PRK1 K644E (Fig. 2a) . The GST control protein is not phosphorylated, thus demonstrating specificity. Furthermore, addition of Ro318220 completely blocks the phosphorylation of GST-H3 1-44 by PRK1 (Fig. 2a) . Deletion mapping revealed that only the fragment of histone H3 spanning amino-acid residues 1-15 (H3 1-15), but not H3 16-30 or H3 29-44, is phosphorylated by purified recombinant PRK1 (Fig. 2b) . More importantly, mutation of threonine 11 to alanine in either H3 1-15 (H3 1-15 T11A) or full-length H3 (H3 1-135 T11A) abolishes phosphorylation, demonstrating that PRK1 targets histone H3 at threonine 11 (H3T11) (Fig. 2b ). In addition, we incubated nucleosomes purified from HeLa cells with recombinant PRK1 in the presence or absence of Ro318220. Western blot analysis, performed with an α-H3T11ph-specific antibody (ref. 7 , and Supplementary Information, Fig. S2a-d) , demonstrates that PRK1 phosphorylates nucleosomes at H3T11 (Fig. 2c) . This phosphorylation is blocked by Ro318220 (Fig.  2c, left panel) . Furthermore, nucleosomes purified from LNCaP cells treated with R1881 were phosphorylated at H3T11, demonstrating that phosphorylation at H3T11 occurs in a ligand-dependent manner in vivo (Fig. 2c , right panel, and Supplementary Information, Fig. S2e ).
To determine whether PRK1 controls phosphorylation of H3T11 at promoters of androgen receptor-regulated genes in vivo, LNCaP cells were first transfected with either an unrelated control small small interfering RNA (siRNA) or an siRNA directed against PRK1, in the (siRNA) or an siRNA directed against PRK1, in the presence or absence of R1881, and then subjected to ChIP. Addition of ligand results in phosphorylation of H3T11 at the AREs of the PSA and KLK2 promoters (Fig. 2d , left panel, and Supplementary  Information, Fig. S2f ). Androgen-induced phosphorylation at H3T11 is PRK1-dependent because it is blocked by knockdown of PRK1. PRK1 depletion is specific and does not affect the levels of endogenous androgen receptor (Fig. 2d, right panel) . To corroborate that androgen-induced phosphorylation of H3T11 is executed by PRK1, LNCaP cells were cultivated in the presence or absence of Ro318220 and subjected to ChIP. As expected, Ro318220 efficiently blocks ligand-induced phosphorylation of H3T11 (Fig. 2e , and Supplementary Information, Fig. S2g ). Taken together, these data demonstrate that PRK1 phosphorylates H3T11. Importantly, the phosphorylation of H3T11 associates with androgen receptordependent gene expression, thus introducing H3T11ph as a novel chromatin mark for transcriptional activation.
PRK1 controls modifications of histone H3
Because ligand-dependent expression of androgen receptor target genes demands removal of repressive methyl marks from H3K9 (refs 3, 4) and acetylation of histone H3K9/K14 (ref. 5), we analysed whether PRK1 controls changes in these histone marks. Therefore, LNCaP cells cultivated in the presence or absence of R1881 were transfected with either an unrelated control siRNA or a siRNA directed against PRK1 and subjected . Western blot analysis (a, right panel) verified the specific miRNA-mediated knockdown of PRK1 (bars represent mean + s.d., n = 4). ChIP and Re-ChIP (c) using the indicated antibodies demonstrate androgen dependent association of androgen receptor and PRK1 at promoters of androgen receptor-regulated genes. The precipitated chromatin was amplified by PCR using primers flanking the AREs in the promoter region of the PSA and KLK2 genes, or the promoters of the unrelated GAPDH and U6 genes.
to ChIP. Ligand-induced demethylation of tri-, di-and monomethyl H3K9 at the AREs of the PSA and KLK2 promoters is severely impaired by PRK1 knockdown (Fig. 3a , and Supplementary Information, Figs S2h and S3a, c-h). Furthermore, ligand-induced acetylation of H3K9/K14 is also blocked (Fig. 3a) . Similarly, inhibition of PRK1 activity by Ro318220 results in loss of demethylation of H3K9 and acetylation of H3K9/K14 (Fig. 3b, and Supplementary Information, Fig. S3b, i-n) , demonstrating that the kinase activity of PRK1 is pivotal in controlling these alterations in histone marks at androgen receptor target genes.
As previously shown, JMJD2C (ref. 4) and LSD1 (ref.
3) remove repressive methyl marks from H3K9 during androgen receptor-dependent transcription. Because PRK1 controls demethylation of H3K9, we investigated the interplay between PRK1 and the demethylases during gene expression in transient transfections. Co-expression of androgen receptor with either JMJD2C (Fig. 3c , and see ref. 4) or LSD1 (Fig. 3d, and see ref. 3) results in a strong ligand-dependent activation of the PSA-LUC or MMTV-LUC reporters. Co-activation by the demethylases is abrogated by PRK1 K644E, acting as a dominant negative mutant, or by treatment with Ro318220. To examine the effect of PRK1 K644E on cooperative stimulation of androgen receptor activity by JMJD2C and LSD1, we expressed both demethylases in limited amounts, which alone do not activate androgen receptor, but together induce a strong androgen receptor superactivation 4 . As shown in Fig. 3e , PRK1 K644E blocks cooperative stimulation of androgen receptor activity. The control reporter TK-LUC is not affected by PRK1 ( Supplementary Information, Fig. S4a-c) . Collectively, these data demonstrate that PRK1 signalling controls transcriptional activation of androgen receptor by the demethylases JMJD2C and LSD1.
PRK1 controls transition to the initiation complex
Initiation of transcription requires transition from the pre-initiation to the initiation complex, which is characterized by phosphorylation of RNA polymerase II at serine 5 in the carboxy (C)-terminal repeat To determine whether depletion or inhibition of PRK1 interfered with the formation of the transcriptional initiation complex at androgen receptor-regulated promoters, we performed ChIP with an antibody that specifically recognizes S5-P CTD pol II. Importantly, knockdown of PRK1 or treatment of cells with Ro318220 results in the loss of S5-P CTD pol II at the promoters of PSA and KLK2. In contrast, recruitment of RNA polymerase II is not affected, as shown by ChIP with an antibody directed against the N-terminal domain of RNA polymerase II (α-NTD pol II) (Fig. 4a, b , and Supplementary Information, Fig. S4d,  e) . Together, these data show that PRK1 not only controls changes in histone marks, but also regulates the transition from pre-initiation to initiation complex.
H3T11ph accelerates demethylation
To gain mechanistic insight into the role of H3T11 phosphorylation during transcriptional regulation, we asked whether PRK1 knockdown or inhibition with Ro31220 affects the presence of JMJD2C and LSD1 on the promoters of the PSA and KLK2 genes. As shown in Fig. 4a, b , the presence of JMJD2C and LSD1 is influenced neither by depletion nor inhibition of PRK1, and PRK1 does not phosphorylate JMJD2C, LSD1 or androgen receptor ( Supplementary Information,  Figs S4f, g and 5a) . In addition, ChIP reveals that PRK1 does not regulate the presence of the H3K9 methyltransferases G9a (ref. Supplementary  Information, Fig. S5c-e) .
Next, we asked whether nucleosomes trimethylated at H3K9 and phosphorylated at H3T11 might serve as better substrates for JMJD2C and thereby accelerate demethylation. We phosphorylated nucleosomes at H3T11 in vitro and performed demethylation assay with bacterially expressed and purified JMJD2C. Importantly, nucleosomes phosphorylated by PRK1 at H3T11 are more rapidly demethylated by JMJD2C compared with unmodified nucleosomes (Fig. 4d) . Together, these data show that H3T11ph activates androgen receptor-dependent transcription by enhancing JMJD2C-dependent demethylation. 
H3T11ph levels correlate with malignancy of prostate cancer
To unravel the physiological importance of PRK1, we investigated the levels of PRK1 and H3T11ph in vivo by immunostaining a panel of 20 normal human prostates and 111 prostate carcinomas on serial cone biopsies from prostate cancers prepared in an arrayed fashion (tissue microarrays) 11 . Quantification of immunoreactivity by scoring staining intensity and percentage of positive carcinoma cells 12 reveals that high PRK1 and H3T11ph levels significantly correlate with high Gleason scores and indicate aggressive biology of the tumours (Fig. 5a-c) . Furthermore, to examine whether PRK1 regulates proliferation of tumour cells, we monitored androgen-dependent cell growth by quantifying proliferation of pLenti6-miRNA-PRK1-infected LNCaP cells. Compared with cells expressing an unrelated control miRNA, androgen-induced proliferation of LNCaP cells is dramatically reduced by PRK1 knockdown (Fig. 5d) . Similar results were obtained by using the PRK1 inhibitor Ro318220 ( Supplementary Information, Fig. S5f ), thus underlining the importance of PRK1 in the control of androgen receptordependent growth of tumour cells.
DISCUSSION
In this manuscript, we demonstrate that phosphorylated H3T11 is a novel chromatin mark for transcriptional regulation. Phosphorylation of H3T11 is executed by PRK1 in an androgen-dependent manner and enhances demethylation of H3K9 by JMJD2C. By controlling subsequent steps of gene activation such as demethylation of tri-, di-and monomethyl H3K9, acetylation of H3K9/K14 and the presence of S5-P CTD pol II at target promoters, PRK1 functions as a gatekeeper of androgen receptor-regulated gene expression.
At androgen receptor target promoters, phosphorylation of T11 by PRK1 represents an activating chromatin mark required for demethylation of H3K9. In vitro, we demonstrate that phosphorylation of H3T11 by PRK1 accelerates demethylation by JMJD2C. Conversely, phosphorylation of the adjacent serine 10 (H3S10) has been shown to block demethylation of trimethylated H3K9 peptides by JMJD2A (ref. 13 ), a close homologue of JMJD2C. In full agreement with this report, we did not observe ligand-induced phosphorylation of H3S10 at androgen receptor target promoters by PRK1 after 30 min ( Supplementary  Information, Fig. S2e ). In contrast, it has been reported that H3S10 phosphorylation is necessary for Myc-dependent transcriptional activation and oncogenic transformation 14 . However, the mechanisms involved are yet to be fully understood.
PRK1 also regulates the transcriptional activity of other nuclear receptors such as mineralocorticoid and progesterone receptor 6 , possibly by a mechanism similar to that controlling androgen receptor target gene expression. This raises questions whether other transcription factors are regulated by PRK1, and whether there exist other H3T11 kinases that control the activity of specific transcription factors. Recently, Dlk/ZIP has been described as phosphorylating H3T11 during mitosis 7 . However, we did not find any evidence that Dlk/ZIP can affect the transcriptional activity of androgen receptor ( Supplementary  Information, Fig. S5g, h ). Because the molecular mechanisms of Dlk/ ZIP-mediated phosphorylation of H3T11 remain unclear, it will be interesting to investigate whether the kinase associates with other transcription factors.
A recent study 15 revealed that histone methylation prevents nuclear receptors and other classes of regulated transcription factors from constitutive gene activation in the absence of stimulating signals. In full agreement with these data, we detect methylated H3K9 at androgen receptor target promoters in the absence of ligand, whereas addition of ligand induces demethylation (Fig. 3a, b) . Intriguingly, PRK1 knockdown or inhibition results in increased H3K9 methylation levels, even in the absence of ligand (Fig. 3a, b) . Although clarification of this observation requires detailed investigation, we hypothesize that this increase could be due to the existence of an androgen receptor-independent pathway of PRK1 signalling, which inhibits histone methyltransferases. Blocking PRK1 would thus activate methyltransferases, resulting in increased methylation levels of H3K9. We speculate that the androgen receptor-independent targeting of methylases by PRK1 might help to fine-tune the methylation status of specific histone marks and prevent formation of a permanently repressive chromatin environment.
The levels of PRK1 and H3T11ph directly correlate with Gleason scores of prostate carcinomas. This finding not only suggests a role for PRK1 in tumourigenesis but also indicates that PRK1, like LSD1 (ref. 12) , may serve as a predictive tumour marker. Of importance is our observation that inhibitors such as Ro318220 control the kinase activity of PRK1 and thereby regulate androgen receptor. Thus, specific modulation of PRK1 activity is a promising therapeutic strategy in the treatment of prostate cancer, where androgen receptor is pivotal to the control of tumour cell proliferation. 
